Biopharmaceutical manufacturer Biogen yesterday became the 19th prescription drug company to announce conditions on 340B pricing when covered entities contract with outside pharmacies.
Massachusetts-based Biogen posted a Dec. 12 letter to entities and an accompanying FAQ describing its new policy on drug industry contractor 340B ESP’s website. Its pricing limitation apply only Avonex and Plegridy, both of them injectable treatments for relapsing multiple sclerosis. Biogen reported $1.5 billion in revenue on the two medicines in 2021 on $10.9 billion in total global revenue.
Biopharmaceutical manufacturer Biogen yesterday became the 19th prescription drug company to announce conditions on 340B pricing when covered entities contract with outside pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
